Relative sparing of calretinin containing neurons in the substantia nigra of 6-OHDA treated rat Parkinsonian model

Brain Research

Volumn 855, Issue 1, 2000, Pages 162-165

  Kim, Byung Gon ^a   Shin, Dong Hoon ^a   Jeon, Gye Sun ^a   Seo, Je Hoon ^a   Kim, Yong Wook ^a   Jeon, Beom Seok ^a   Cho, Sa Sun ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Calcium binding protein; Calretinin; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

CALRETININ; OXIDOPAMINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL CULTURE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CELL SURVIVAL; MALE; NEURONS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE;

EID: 0342614913     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)02374-4     Document Type: Article

References (27)

1. Baimbridge K.G., Miller J.J., Parkes C.O. Calcium-binding protein distribution in the rat brain. Brain Res. 239:1982;519-525.
2. Baimbridge K.G., Celio M.R., Rogers J.H. Calcium-binding proteins in the nervous system. Trends Neurosci. 15:1992;303-308.
3. Blumcke I., Beck H., Nitsch R., Eickhoff C., Scheffler B., Celio M.R., Schramm J., Elger C.E., Wolf H.K., Wiestler O.D. Preservation of calretinin-immunoreactive neurons in the hippocampus of epilepsy patients with Ammon's horn sclerosis. J. Neuropathol. Exp. Neurol. 55:1996;329-341.
4. Fonseca M., Soriano E. Calretinin-immunoreactive neurons in the normal human temporal cortex and in Alzheimer's disease. Brain Res. 691:1995;83-91.
5. German D.C., Manaye K.F., Sonsalla P.K., Brooks B.A. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced Parkinsonism: sparing of calbindin-D28K containing cells. Ann. N.Y. Acad. Sci. 648:1992;42-62.
6. Hirsch E.C. Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease? Ann. Neurol. 32:1992;S88-S93.
7. Iacopino A., Christakos S., German D.C., Sonsalla P.K., Altar C.A. Calbindin D28K-containing neurons in animal models of neurodegeneration. Mol. Brain Res. 13:1992;251-261.
8. Isaacs K.R., Jacobowitz D.M. Mapping of the colocalization of calretinin and tyrosine hydroxylase in the rat substantia nigra and ventral tegmental area. Exp. Brain Res. 99:1994;34-42.
9. Jande S.S., Tolnai S., Lawson D.E. Immunohistochemical localization of vitamin D-dependent calcium-binding protein in duodenum, kidney, uterus and cerebellum of chickens. Histochemistry. 71:1981;99-116.
10. Jenner P., Schapira A.H., Marsden C.D. New insights into the cause of Parkinson's disease. Neurology. 42:1992;2241-2250.
11. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 47:1996;S161-S170.
12. Koller W.C. Neuroprotective therapy for Parkinson's disease. Exp. Neurol. 144:1997;24-28.
13. Kotti T., Tapiola T., Riekkinen P.J. Sr., Miettinen R. The calretinin-containing mossy cells survive excitotoxic insult in the gerbil dentate gyrus. Comparison of excitotoxicity-induced neuropathological changes in the gerbil and rat. Eur. J. Neurosci. 8:1996;2371-2378.
14. Lee C.S., Sauer H., Björklund A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-OHDA in the rat. Neuroscience. 72:1996;641-653.
15. LeWitt P.A. Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. The Parkinson Study Group. Acta Neurol. Scand. Suppl. 136:1991;79-86.
16. Lindsay R.M., Altar C.A., Cedarbaum J.M., Hyman C., Wiegand S.J. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease. Exp. Neurol. 124:1993;103-118.
17. Lukas W., Jones K.A. Cortical neurons containing calretinin are selectively resistant to calcium overload and excitotoxicity in vitro. Neuroscience. 61:1994;307-316.
18. McRitchie D.A., Hardman C.D., Halliday G.M. Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. J. Comp. Neurol. 364:1996;121-150.
19. Mouatt-Prigent A., Agid Y., Hirsch E.C. Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease? Brain Res. 668:1994;62-70.
20. G. Paxinos, C. Watson, The rat brain in stereotaxic coordinates, Academic Press, Australia, 1986.
21. Poewe W.H., Wenning G.K. The natural history of Parkinson's disease. Neurology. 47:1996;S146-S152.
22. Przedborski S., Levivier M., Jiang H.et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience. 67:1995;631-647.
23. Résibois A., Rogers J.H. Calretinin in rat brain: an immunohistochemical study. Neuroscience. 46:1992;101-134.
24. Rogers J.H. Calretinin: a gene for a novel calcium-binding protein expressed principally in neurons. J. Cell Biol. 105:1987;1343-1353.
25. Rogers J.H. Immunohistochemical markers in the rat brain: colocalization of calretinin and calbindin-D28K with tyrosine hydroxylase. Brain Res. 587:1992;203-210.
26. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-OHDA: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience. 59:1994;401-415.
27. Yamada T., McGeer P.L., Baimbridge K.G., McGeer E.G. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 526:1990;303-307.